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AutophagosomesHerewe report that focal adhesion kinase (FAK) is required for optimal signalling to the Akt-p70S6K-S6 pathway
in squamous cell carcinoma (SCC) cells. Speciﬁcally, in SCCs that are genetically deﬁcient for FAK, there is reduced
phosphorylation of Akt, p70S6K and S6, and signalling to Akt-p70S6K-S6 is more sensitive to inhibition by
multiple agents that suppress the pathway. By contrast, mTOR is unaffected. Indeed, pharmacological agents
that inhibit the Akt-p70S6K-S6pathway, and PDK1 that lies upstreamof Akt, also impair the autophagic targeting
of activated c-Src (p-Src) in FAK deﬁcient cells. This is associated with loss of a complex between p-Src and the
autophagy protein LC3, a biochemical surrogate of impaired Src-selective autophagy. In keeping with a vital
role for p70S6K, inhibition by a selective inhibitor and speciﬁc siRNA also impaired Src-selective autophagy. Fi-
nally, components of the PDK1-Akt-p70S6K signalling pathway were co-located with p-Src at autophagosomes,
and Src and p70S6K co-exist in the same biochemical complex. We therefore deduce that the FAK-regulated
signalling module PDK1-Akt-p70S6K that controls Src's intracellular trafﬁcking operates at Src-containing
autophagosomes.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Src is a member of a family of non-receptor tyrosine kinases that
control cell adhesion, invasion, proliferation, survival and angiogenesis
[1]. Overexpression or activation of Src proteins occurs in a number of
human cancers and is frequently linked to poor clinical outcome [2–4],
although the molecular mechanisms that cancer cells use to maintain
and copewith elevated levels of promiscuous activated tyrosine kinases
like Src are poorly understood.
Src consists of a myristoylation domain, unique and Src homology 3
and 2domains (SH3and SH2), a kinase domain containing anautophos-
phorylation site at Tyr 416 (Y416) and a C-terminal regulatory region.
Activation results in phosphorylation of Y416 and allows the SH3
and SH2 domains to bind to important partner proteins, including
focal adhesion kinase (FAK). Recently we perturbed ﬂux through the
Src/FAK pathway in SCC cells, and identiﬁed a new mechanism for
regulating high levels of active Src kinase [5]. Brieﬂy, genetic deletion
of the gene encoding FAK, detachment of FAK-proﬁcient cells or expres-
sion of non-phosphorylatable FAK proteins promotes trafﬁcking ofof Medical, Veterinary and Life
G61 1BD, United Kingdom.
. This is an open access article underactive Src from peripheral focal adhesions to cytoplasmic puncta that
contain autophagy proteins. Sequestration in these untypically regulat-
ed autophagosomes requires the formation of a complex between Src
and LC3B, a known autophagy cargo receptor [6,7], and this is mediated
by c-Cbl [5]. Disruption of this process results in restoration of active Src
at peripheral adhesions and loss of the LC3B/Src complex. This autoph-
agic targeting of Src allows these FAK deﬁcient cancer cells to deal with
elevated levels of active Src kinase that is not spatially controlled by its
tethering partner FAK [5].
Typically, engagement of autophagy occurs during metabolic stress
when cells need to reallocate nutrients, or when speciﬁc protein aggre-
gates, mis-folded proteins, organelles, bacteria or viruses need to be
removed. This process involves a number of distinct steps that are all
tightly regulated by a family of autophagy-related (ATG) proteins, the
secretory and endocytic pathways, the cytoskeletal network, transcrip-
tion factors, post-translational modiﬁcations and protein kinase signal-
ling cascades [8,9]. What we described was an adhesion stress-induced
form of autophagy that does not seem to be dependent upon nutrient
starvation [5] and was highly selective for the targeting of FAK-
tethered oncogenic kinases, such as Src and Ret [5,10]. In the current
work,we identiﬁed the signalling requirements of Src-selective autoph-
agy. We found that FAK regulates phosphorylation of Akt, p70S6K and
S6, and that components of the PDK1-Akt-p70S6K-S6 signalling path-
way were co-located in Src-containing autophagosomes. Crucially, the
activity of p70S6K, but not mTOR, was required for Src-selective
autophagy triggered by FAK loss.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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2.1. Antibodies
Antibodies used were: anti-p-Src Y416, anti-Src 36D10, anti-LC3B,
anti-FAK, anti-p-PDK1 S241, anti-PDK1, anti-p-Akt S473, anti-Akt,
anti-GAPDH, anti-p-mTOR S2448, anti-p-mTOR S2481, anti-mTOR,
anti-p-S6 S235/236, anti-p-S6 S240/244, anti-S6, anti-p-p70S6K T389,
anti-p70S6K, anti-mouse and anti-rabbit IgG-peroxidase conjugated
secondary antibodies (all New England Biolabs, Herts, UK), anti-LC3
(MBL, MA, USA), and anti-paxillin (BD Transduction Laboratories, Ox-
ford, UK). Alexa 488 and Alexa 594 conjugated secondary antibodies,
Deep Red Cell Mask and Vectashield microscope mounting medium
with DAPI were from Invitrogen (Paisley, UK).
Tocriscreen Kinase Inhibitor Toolbox, SB218078, SB216763,
ZM306416, PD407824, BIO, Ki8751 and PF4708671 were all from R &
D (Abington, UK), hygromycin B from Merck Biosciences (Nottingham,
UK), dasatinib from Bristol Myers Squibb (Middlesex, UK) and 3MA
from Sigma (Poole, UK). The Micro BCA Protein Assay Kit was from
Pierce Ltd. (Northumbria, UK), Lipofectamine2000 from Invitrogen
(Paisley, UK) and HiPerFect from Qiagen (Crawley, UK). siRNA was
from Dharmacon (Colorado, USA).
2.2. Generation of FAK-deﬁcient squamous cell carcinoma cells
K14CreERT2/FAKﬂox/ﬂox mice were subjected to chemical carcinogen-
esis [11] and FAK positive cells grown from the resultant tumours as
described previously [5]. FAK was deleted using 10 μM of 4-hydroxy
tamoxifen (4-OHT) and stable single cell clones generated that were
FAK deﬁcient (FAK−/−) [5].
2.3. Cell culture and transfection
Cells were cultured in Glasgow Minimum Essential Medium (10%
foetal calf serum, 2 mM L-glutamine, NEAA, sodium pyruvate and
MEM vitamins). Phoenix Eco cells were transfected with pWZL-FAK-
WT using Lipofectamine2000 (as per manufacturers instructions) and
the supernatant from these cells used to infect FAK−/− SCC using
10 μg/ml polybrene. These FAK-WT SCC cells were then selected and
maintained in 1 mg/ml hygromycin B.
2.4. Kinase inhibitor screen
FAK−/− and FAK-WT SCC cells were plated on ﬂat-bottomed
96-well glass plates overnight. Then 80 kinase inhibitors from the
Tocriscreen Kinase Inhibitor Toolbox were added at 1 μM, 10 μM or
20 μM for 24 h. Plates were washed in TBS and ﬁxed for 10 min
(formaldehyde (3.7%), K-Pipes pH 6.8 (100 mM), EGTA (10 mM),
MgCl2 (1 mM), Triton X-100 (0.2%)). After three washes (in TBS con-
taining 0.1% Triton X-100) plates were blocked in TBS containing
0.1% BSA for 1 h prior to overnight incubation with anti-p-Src
Y416. Primary antibody was washed off and a ﬂuorescently labelled
secondary antibody (Alexa 488) and Deep Red Cell Mask were added
for 45 min. After three washes (TBS with 0.1% Triton X-100) DAPI
(diluted 1 in 1000 in PBS) was added for 10 min. Plates were washed
twice in PBS and each well imaged using an Olympus Scan-R
microscope.
Data were analysed using Scan-R analysis software to calculate the
number of puncta (based on size and shape of Src positive puncta) per
cell (calculated using DAPI). Untreated FAK-WT or FAK−/− cells were
used as a negative (15 puncta per cell) and positive (58 puncta per
cell) control respectively and the number of Src positive puncta per
cell was calculated after treatment with each inhibitor. Each image
taken by the Scan-R was also examined to identify any general pheno-
typic changes, cell death or focusing issues. Of the 80 inhibitors tested
20 induced an obvious change in the localization of active Src and/or asigniﬁcant reduction in the number of puncta detected. These inhibitors
were then validated as described below.
2.5. Immunoﬂuorescence
Cells were plated on glass coverslips overnight, treated with inhibi-
tor for 24 h then ﬁxed and stained as described above. Inhibitors
were used at the following concentrations: 3MA (10 mM), dasatinib
(100 nM), SB218078 (A; 1 μM), PD407824 (B; 10 μM), SB216763 (C;
10 μM), BIO (D; 10 μM), ZM306416 (E; 20 μM), Ki8751 (F; 10 μM) and
PF4708671 (10 μM). Primary antibodies were diluted 1:100 except
paxillin and p-Src Y416, whichwere used at 1:500. Imagingwas carried
out using an FV1000 Olympus Confocal Microscope. Image analysis was
carried out using ImageJ. Images shown are representative of three
separate experiments.
2.6. Immunoblotting and immunoprecipitation
Cells were washed with PBS, lysed in either NP40 lysis buffer
(50 mM Tris–HCL at pH 8, 150 mM NaCl, 0.5% NP40) or MD Anderson
buffer (1% Triton X 100, 50 mM Hepes pH 7.4, 150 mM NaCl, 1.5 mM
MgCl2 and 1 mM EGTA) containing a protease and a phosphatase inhibi-
tor tablet (Sigma) and centrifuged for 15min at high speed (16,000 ×g at
4 °Cmin). A protein assaywas then carried out using aMicro BCA Protein
AssayKit. 1mgof lysatewas used to collect immune complexes by immu-
noprecipitation using 2 μg of antibody or control IgG. Beads were washed
three times in lysis buffer before a ﬁnal wash using 0.6 M LiCl was per-
formed. These samples or 20 μg lysate were then supplemented with
sample buffer (Tris at pH 6.8, 20% glycerol, 5% SDS, β-mercaptoethanol
and bromophenol blue), separated by SDS-PAGE, transferred to nitrocel-
lulose membrane and then immunoblotted with speciﬁc antibodies.
Blots shown are representative of three experiments.
2.7. siRNA-mediated protein knockdown
80 nMScrambled (Cat no.: D-001206-13-20), Rps6kb1 1 or Rps6kb1
2 siRNA (Cat no.: D-040893-02 and D-040893-04) were transiently
transfected into FAK−/− cells using HiPerFect. Cells were left for 24 h
then re-plated onto glass coverslips or 100 mm tissue culture plates
for a further 24 h prior to immunoﬂuorescence or immunoblotting.
2.8. Statistical tests
For all experiments shown n= 3. Quantiﬁcation was carried out by
counting 50 cells and calculating the percentage of cells with each phe-
notype after each experiment. Graphs shown throughout the paper
show the average percentage and error bars all represent s.d. A
Student's T-Test was performed where appropriate to calculate the
statistical signiﬁcance and p values are stated in the Figure Legends.
3. Results
3.1. p70S6K is regulated by FAK and is involved in Src's spatial regulation
In examining effects of FAK depletion upon signalling pathways,
we found that phosphorylation of Akt (S473), p70S6K (T389) and its
downstream target S6 (S235/236 and S240/244) were all reduced in
FAK−/− SCCs, while phosphorylation of mTOR (S2448; a key determi-
nant of mTOR activation [12] or its auto-phosphorylation site (2481))
were unaffected (Fig. 1A; reductions quantiﬁed in Fig. 1B). This shows
that signalling to Akt, p70S6K and S6 was at least partly dependent on
FAK in SCC cells.
In previous work, we showed that p-Src predominantly localised to
distinctive cytoplasmic puncta in FAK-deﬁcient SCC cells (Supplementa-
ry Fig. 1A, broken arrows, quantiﬁed in right panel), and this was
rescued by re-expression of wild type FAK (FAK-WT), causing p-Src to
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Fig. 1. Src trafﬁcking to autophagosomes is dependent upon p70S6K. (A) Cell lysates from SCC FAK-WT and FAK−/− cells were immunoblotted with anti-p-mTOR S2448, anti-p-mTOR
S2481, anti-mTOR, anti-p-Akt S473, anti-Akt, anti-p-p70S6K T389, anti-p70S6K, anti-p-S6 S235/236, anti-p-S6 S240/244, anti-S6 and anti-GAPDH. (B) Graph shows the relative
ratio of p-p70S6K/total p70S6K, p-S6 S235/236/total S6 and p-Akt S473/total Akt in FAK-WT and FAK−/− cells. Results are presented as mean ± s.d. and signiﬁcance is p b 0.01
(n= 8). (C) FAK−/− cells were treated with the p70S6K inhibitor PF4708671 (10 μM) for 24 h. Cell lysates were immunoblotted with anti-p-Akt S473, anti-Akt, anti-p-p70S6K
T389, anti-p70S6K, anti-p-S6 S235/236, anti-p-S6 S240/244, anti-S6, anti-p-Src Y416, anti-Src and anti-GAPDH. (D) Cells were also ﬁxed and stained for anti-p-Src Y416 (green) and DAPI (blue). Broken
arrows showactive Src localising topunctawhile solid arrows indicate active Src localising to adhesions. Quantiﬁcation shows thepercentage of cellswith active Src localising to intracellular puncta. Results
arepresentedasmean±s.d. and signiﬁcance ispb 0.01 (n=3). (E) LC3Bwas immunoprecipitated fromFAK−/− cells treatedwithPF4708671and immunoblottingperformedwithanti-p-SrcY416and
anti-LC3B. (F) FAK−/− cellswere transfectedwith either 80 nMScrambled, p-70 S6K1 or p-70 S6K2 siRNA for 48 h. Immunoblotting carried out using anti-p70S6K and anti-GAPDHantibodies. (G) Cells
were alsoﬁxed and stained for anti-p-Src Y416 (green), anti-paxillin (red) andDAPI (blue). Broken arrows showactive Src localising to punctawhile solid arrows indicate active Src localising to adhesions.
Scale bars: 20 μm. Quantiﬁcation shows the percentage of cells with active Src localising to intracellular puncta. Results are presented asmean± s.d. and signiﬁcance is p b 0.01 (n= 3).
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1819E. Sandilands et al. / Cellular Signalling 27 (2015) 1816–1823be restored at focal adhesions (Supplementary Fig. 1A, solid arrows,
quantiﬁed in right panel). The cytoplasmic punctate structures that
are prominent in FAK-deﬁcient cells also contain autophagy proteins
such as LC3B and ATG proteins, but not paxillin [5,10]. Since p70S6K
has previously been implicated in the regulation of speciﬁc forms of
autophagy [13–16], we addressed whether the trafﬁcking of active Src
to autophagic puncta in FAK-deﬁcient SCC cells was dependent on
p70S6K by ﬁrst using the pharmacological inhibitor PF4708671. As ex-
pected, this caused decreased p-S6 (S235/236 and S240/244; Fig. 1C),
despite increased levels of p-p70S6K (perhaps by inhibition of a nega-
tive feedback mechanism) and impaired sequestration of p-Src into
autophagosomes; instead, p-Src was restored at focal adhesions
(Fig. 1D, solid arrows, quantiﬁed in right panel). Importantly, the
p70S6K inhibitor did not affect p-Src levels in FAK−/− cells as judged
by immunoblotting (Fig. 1E, lower panels). We also previously showed
that LC3B is present in a complex with p-Src in the absence of FAK [5]
(Supplementary Fig. 1D), providing biochemical evidence of the for-
mation of an autophagy-associated, Src-containing complex. The
LC3B/p-Src Y416 complex was substantially reduced in FAK-deﬁcientA FAK -/- cells
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and anti-LC3B antibodies.cells upon p70S6K inhibitor treatment (Fig. 1E), providing biochemical
evidence of impaired Src-selective autophagy. Since kinase inhibitors
are rarely speciﬁc, we efﬁciently depleted p70S6K in FAK-deﬁcient
cells using two speciﬁc siRNAs (Fig. 1F). Loss of p70S6K protein resulted
in signiﬁcant reduction in the number of p-Src-containing puncta and
restoration of active Src to paxillin-containing focal adhesions (Fig. 1G,
broken arrows, quantiﬁed in right panel). Taken together, these data
indicate that p70S6K controls Src's autophagic targeting when FAK is
absent.
3.2. Identifying pharmacological agents that inhibited Src's autophagic
targeting
Next we performed a small drug screen using a commercially avail-
able kinase inhibitor library. Adherent FAK−/− cells were treated with
80 different kinase inhibitors (Tocriscreen Kinase Inhibitor Toolbox) for
24 h, then ﬁxed and stained with p-Src Y416 antibody, Deep Red Cell
Mask and DAPI, so as to visualise autophagosomes and adhesions, cell
cytoplasm and nucleus, respectively. Cells were imaged and analysedLC3B
p-Src Y416
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ibitors A–F for 24 h. Cells were ﬁxed and stainedwith anti-p-Src Y416 (green), anti-paxillin
racellular structures was quantiﬁed and data presented as mean ± s.d. Signiﬁcance for all
eated with kinase inhibitors. Then immunoblotting was performed using anti-p-Src Y416
1820 E. Sandilands et al. / Cellular Signalling 27 (2015) 1816–1823using an Olympus Scan-R microscope to calculate the number of Src-
positive puncta per cell in untreated FAK-WT (less than 15 puncta per
cell) and untreated FAK−/− (58 puncta per cell) cells as negative and
positive controls. We focused on 6 chemical entities that signiﬁcantly
reduced the number of Src-positive puncta detected per cell (Fig. 2A
and quantiﬁed in 2B), but were not in the class of chemicals that
would inhibit Src phosphorylation per se (for example, there was no
signiﬁcant decrease in either the amount of total or active Src after treat-
ment of FAK-WT cells with these agents) (Supplementary Fig. 1C,
middle and upper panels respectively). Moreover, the formation of the
LC3B/Src complex was reduced after treatment with all 6 kinase inhib-
itors, providing biochemical evidence of inhibition of Src's targeting to
intracellular puncta that supported the imaging data (Fig. 2C and lysates
shown in Supplementary Fig. 1C and 1E). The screen was validated
using inhibitors that are known to block general autophagy (3MA
[17]) or Src phosphorylation (dasatinib [5]), and these, as expected,
blocked visualisation of active Src at autophagic puncta in FAK−/−
cells (Supplementary Fig. 1B). For the 6 inhibitors we identiﬁed, termed
A–F, we wished to take an unbiased view on their mode of action since
we believed that they are relatively non-speciﬁc kinase inhibitors
(details of these inhibitors can be found in Table 1). Next, we examined
how these affected the Akt/p70S6K/S6 pathway (and PDK1 upstream)
that we knew to control Src's autophagic targeting (Fig. 1).3.3. Kinase inhibitors selected to disrupt Src-selective autophagy inhibit
signalling to PDK1, Akt, p70S6K and S6
We investigated the effects of the 6 pharmacological agents (A–F).
All inhibitors (with the exception of one, namely inhibitor C) caused a
robust reduction in p-PDK1 and total PDK1, particularly notable in
FAK-deﬁcient cells. Treatment with inhibitor C resulted in a small
increase in total PDK1 in FAK−/− cells (Fig. 3A). All 6 inhibitors
caused reduced phosphorylation of Akt, most prominently in FAK-
deﬁcient cells (Fig. 3A, quantiﬁed in lower panels).
Akt signalling is reported to suppress autophagy in response tomito-
gens, via activation of mTOR [18]. In this latter study, PDK1 phosphory-
lated and activated Akt, which in turn phosphorylated and inhibited the
activity of TSC1/TSC2 complex — a negative regulator of mTOR [18].
Since the PDK1/Akt pathway has been shown to inﬂuence autophagy
via mTOR in multiple contexts, we used phospho-speciﬁc antibodies
to study the expression and phosphorylation of mTOR at Ser2448, a
key determinant of its activity [12], and at its autophosphorylation site
Ser2481. We found that both mTOR expression and phosphorylation
were unaffected by any of the 6 kinase inhibitors (Supplementary
Fig. 2), demonstrating that steady state mTOR activity was not inﬂu-
enced by agents that inhibit Src's autophagic targeting. We then inves-
tigated the effect of the 6 inhibitors on phosphorylation of p70S6K
and on the phosphorylation of its S6 substrate. All of the inhibitors
showed remarkable consistency in inhibiting the phosphorylation of:Table 1
A–F inhibitors in this study from Tocriscreen Kinase Inhibitor Toolbox. SCC cells were plated ov
μM, 10 μMor 20 μM for 24 h. Plateswere ﬁxed and stainedwith anti-p-Src Y416, Deep Red CellM
to calculate the number of puncta (based on size and shape of Src positive puncta) per cell (cal
Src. The effect that each inhibitor had on active Src is summarised in this table.
Inhibitor Inhibitor name Target 20 μM
A SB218078 Chk1 Less p-Src Y41
B PD407824 Chk1 Toxic for cells
C SB216763 GSK-3β Less p-Src Y41
D BIO GSK-3β Toxic for cells
E ZM306416 VEGFR Less p-Src Y41
F Ki8751 VEGFR Less p-Src Y41
Note: The above named inhibitors, designatedA–F,were used as agents to inhibit Src-selective a
off target effects.a) p70S6K (Fig. 3B, faster migrating species), and b) S6K on S235/236
and S240/244. Residual phosphorylation was barely detectable by
immunoblotting in the FAK−/− cells (Fig. 3B, quantiﬁcation is shown
for the ratio of p-S6 S235/236/S6 in lower panels).
3.4. Autophagosomes act as sub-locale for signalling to p70S6K
We next examined the intracellular localisation of activated compo-
nents of the PDK1/Akt/p70S6K signalling pathway. We found that all of
these co-localised to autophagic puncta with active Src (Fig. 4A and B
respectively, solid arrows in merged images). Although we observed
mTOR in cytoplasmic puncta, it did not visibly co-localise with p-Src-
containing puncta in FAK-deﬁcient cells (Fig. 2B, lower panels, broken
arrow inmerged image). Ameasure of the co-localisation (or lack there-
of in the case ofmTOR) is presented as distance between intensity peaks
of co-stained proteins (Fig. 2C). We also identiﬁed a biochemical com-
plex that contained both Src and p70S6K, althoughwe have no evidence
that this complex is via direct binding (Fig. 4D). These data imply that
the intracellular puncta that contain autophagy proteins also physically
serve as a sub-locale for the activated kinase components of the signal-
ling pathway – PDK1/Akt/p70S6K –which promotes efﬁcient targeting
of Src to these structures when Src cannot be tethered at focal adhesion
complexes in the absence of FAK.
Taken together, our results imply that the trafﬁcking of active Src to
autophagosomes in FAK-deﬁcient cancer cells is controlled by the
PDK1/Akt/p70S6K pathway. Chemical agents that inhibit Src-selective
autophagy (Fig. 2) also inhibit signalling to PDK1/Akt/p70S6K/S6, and
FAK−/− cells are considerably more sensitive to inhibition (Fig. 3).
Moreover, inhibiting p70S6K results in a block to Src's autophagic
targeting (Fig. 1). Finally, the phosphorylated components of the
PDK1/Akt/p70S6K pathway co-exist with active Src at autophagic
puncta that are dependent on p70S6K (Fig. 4; model depicted in Fig. 4E).
4. Discussion
In this study, we set out to determine the signalling determinants of
the trafﬁcking of active Src to autophagosomes in FAK-depleted SCC
cancer cells. We identiﬁed 6 kinase inhibitors that efﬁciently blocked
the trafﬁcking of active Src to autophagosomes, and all 6 inhibited
signalling to PDK1/Akt/p70S6K/S6, without affectingmTOR phosphory-
lation. The basal levels of p-p70S6K, p-S6K and p-Akt were lower in
untreated FAK-deﬁcient cells, providing theﬁrst evidence that FAK is re-
quired for optimal signalling to p70S6K; we found that FAK-deﬁcient
cells were more sensitive to p70S6K inhibition.
By using a pharmacological inhibitor and siRNA targeting p70S6K, we
conﬁrmed that p70S6K is required for the targeting of active Src to
autophagosomes in the absence of FAK,whereas p70S6K-mediated phos-
phorylation of S6 has previously been correlated with autophagy sup-
pression [13]. However, there are also multiple examples of p70S6K-ernight then the inhibitors from the Tocriscreen Kinase Inhibitor Toolbox were added at 1
ask andDAPI, then imaged using a Scan-Rmicroscope. Scan-R analysis softwarewas used
culated using DAPI) and to identify any alterations to the intracellular localisation of active
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Fig. 3. The PDK1/Akt/p70S6K pathway is linked to Src-selective autophagy. FAK-WT and FAK−/− cells were treatedwith the inhibitors A–F for 24 h. (A) Cell lysates were immunoblotted
with anti-FAK, anti-p-PDK1 S241, anti-PDK1, anti-p-Akt S473, anti-Akt and anti-GAPDH. Graphs show the relative ratio of phospho-Akt S473/total Akt. (B) Cell lysates were
immunoblotted with anti-p-p70S6K T389, anti-p70S6K, anti-p-S6 S235/236, anti-p-S6 S240/244, anti-S6 and anti-GAPDH. Graphs show the relative ratio of p-S6 S235/236/total S6.
1821E. Sandilands et al. / Cellular Signalling 27 (2015) 1816–1823mediated promotion of autophagy. These include studies in Drosophila
where dS6K is required for starvation-induced autophagy [14], in
mammalian cells where resveratrol-induced inhibition of p70S6K im-
pairs the autophagic response [15], and in colorectal cancer cells where
p70S6K positively regulates 6-thioguanine-induced autophagy [16].
Src's autophagic targeting under ‘adhesion stress’ upon deletion of FAK
is therefore another example of dependence on signalling pathways
that converge on p70S6K.
The regulation of Src's localization to autophagosomes by the PDK1/
Akt/p70S6K pathway is accompanied by the co-localisation of compo-
nents of this signalling pathway to Src-containing autophagosomes,
but not mTOR. This implies that the phosphorylation events required
for the recruitment of Src occur at these structures, or during their
assembly or formation. We therefore propose these autophagosomes
represent sub-cellular locale that house the signalling ‘module’ that
activates p70S6K in a spatially-regulated manner, and, in turn, this is
required for efﬁcient targeting of Src to these structures when FAK isabsent (schematic shown in Fig. 4E). This is another example of signal-
ling components being found at autophagosomes; a recent study re-
ported how ATG5/12-positive pre-autophagosomes and LC3B-positive
membranes can act as cellular signalling hubs that facilitate the spatial
co-ordination and activation of the MEK/ERK cascade in NIH 3T3 cells
[19].
5. Conclusions
We have established that: a) p-Akt, p-p70S6K and p-S6K are re-
duced in untreated FAK-deﬁcient SCC cells, and b) inhibition of the
PDK1/Akt pathway leads to inactivation of p70S6K, reduced p-S6K
downstream, and restoration of active Src to focal adhesions in the
absence of FAK (depicted in model Fig. 4). Unlike classical autophagy
signalling, this process did not involve changes to mTOR phosphoryla-
tion and it may be that components of these pathways are able to acti-
vate p70S6Kdirectly, as PDK1has been shown to directly phosphorylate
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ﬂuorescent signals. Results are presented as mean± s.d. (n= 20 intensity peaks from 5 cells). (D) Src was immunoprecipitated from SCC cells and immunoblotting performedwith anti-
p70S6K and anti-Src. (E) Model of signalling at Src positive autophagosomes. Schematic depicting how the use of inhibitors inﬂuences the trafﬁcking of active Src to autophagic puncta in
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1823E. Sandilands et al. / Cellular Signalling 27 (2015) 1816–1823and activate p70S6K in vitro and in vivo [20]. We conclude that p70S6K
is required for the sequestration of active Src away from focal adhesions
and into autophagic puncta, since knock down of its expression and a
speciﬁc kinase inhibitor induces re-localization of Src to peripheral
adhesions. We also conclude that signalling to p70S6K in SCC cancer
cells is FAK-dependent, and that inhibition of p70S6K activation by
drugs that target the upstream kinase pathways is more efﬁcient
when FAK is absent.
Conﬂict of interest
The authors declare no conﬂict of interest.
Acknowledgements
This work was supported by Cancer Research UK (ProgrammeGrant
C157/A15703) and ERC (Advanced Investigator Grant 29440 Cancer
Innovation).
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cellsig.2015.05.017.
References
[1] S.M. Thomas, J.S. Brugge, Annu. Rev. Cell Dev. Biol. 13 (1997) 513–609.[2] H. Aligayer, D.D. Boyd, M.M. Heiss, E.K. Abdalla, S.A. Curley, et al., Cancer 94 (2002)
344–351.
[3] C.A. Cartwright, M.P. Kamps, A.I. Meisler, J.M. Pipas, W. Eckhart, J. Clin. Invest. 83
(1989) 2025–2033.
[4] R.B. Irby, W. Mao, D. Coppola, J. Kang, J.M. Loubeau, et al., Nat. Genet. 21 (1999)
187–190.
[5] E. Sandilands, B. Serrels, D.G. McEwan, J.P. Morton, J.P. Macagno, et al., Nat. Cell Biol.
14 (2012) 51–60.
[6] V. Kirkin, T. Lamark, Y.S. Sou, G. Bjorkoy, J.L. Nunn, et al., Mol. Cell 33 (2009)
505–516.
[7] S. Pankiv, T.H. Clausen, T. Lamark, A. Brech, J.A. Bruun, et al., J. Biol. Chem. 282 (2007)
24131–24145.
[8] T. Yorimitsu, D.J. Klionsky, Cell Death Differ. 12 (Suppl. 2) (2005) 1542–1552.
[9] C. He, D.J. Klionsky, Annu. Rev. Genet. 43 (2009) 67–93.
[10] E. Sandilands, B. Serrels, S. Wilkinson, M.C. Frame, EMBO Rep. 13 (2012) 733–740.
[11] G.W. McLean, N.H. Komiyama, B. Serrels, H. Asano, L. Reynolds, et al., Genes Dev. 18
(2004) 2998–3003.
[12] A. Sekulic, C.C. Hudson, J.L. Homme, P. Yin, D.M. Otterness, et al., Cancer Res. 60
(2000) 3504–3513.
[13] E.F. Blommaart, J.J. Luiken, P.J. Blommaart, G.M. van Woerkom, A.J. Meijer, J. Biol.
Chem. 270 (1995) 2320–2326.
[14] R.C. Scott, O. Schuldiner, T.P. Neufeld, Dev. Cell 7 (2004) 167–178.
[15] S.M. Armour, J.A. Baur, S.N. Hsieh, A. Land-Bracha, S.M. Thomas, et al., Aging (Albany
NY) 1 (2009) 515–528.
[16] X. Zeng, T.J. Kinsella, Cancer Res. 68 (2008) 2384–2390.
[17] D.J. Klionsky, H. Abeliovich, P. Agostinis, D.K. Agrawal, G. Aliev, et al., Autophagy 4
(2008) 151–175.
[18] J. Huang, B.D. Manning, Biochem. Soc. Trans. 37 (2009) 217–222.
[19] N. Martinez-Lopez, D. Athonvarangkul, P. Mishall, S. Sahu, R. Singh, Nat. Commun. 4
(2013) 2799.
[20] D.R. Alessi, M.T. Kozlowski, Q.P. Weng, N. Morrice, J. Avruch, Curr. Biol. 8 (1998)
69–81.
